54 completed, 14 unknown, 6 active not recruiting, 4 terminated. 27 Phase 4, 21 Phase 2, 21 Phase 3, 4 Not applicable, 4 Phase 1.
Follow sofosbuvir-velpatasvir drug combination: new trials by email Literature Review of sofosbuvir-velpatasvir drug combination trials Research Report on sofosbuvir-velpatasvir drug combination
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combating Related Epidemics in HCV Cepheid GeneXpert HCV Test, Abbott Determine HIV - 1/2 Ag/Ab, Abbott Determine HbsAg 2 - HIV - Human Immunodeficiency Virus, Hepatitis B Virus (HBV) | Phase 4 | Not yet recruiting | Duke University | 1280 | 2027-01-20 | 2026-10-15 |
| AI-Powered Hepatitis C Single-Encounter Test-and-Treat Epclusa (sofosbuvir and velpatasvir) - HEPATITIS C (HCV) | Phase 4 | Not yet recruiting | Patrick Grace | 35 | 2026-12-01 | 2026-08-28 |
| Implementing Low-Barrier HCV Treatment in a Jail Setting Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Community Health Worker - HEPATITIS C (HCV), Incarceration | Phase 4 | Recruiting | Lifespan | 40 | 2025-06-11 | 2026-02-27 |
| C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir, Sofosbuvir-Velpatasvir - HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic | Phase 3 | Active not recruiting | Atea Pharmaceuticals, Inc. | 880 | 2025-06-02 | 2026-06-29 |
| C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV Bemnifosbuvir-Ruzasvir (BEM/RZR), Sofosbuvir-Velpatasvir (SOF/VEL) - HEPATITIS C VIRUS CHRONIC INFECTION | Phase 3 | Active not recruiting | Atea Pharmaceuticals, Inc. | 880 | 2025-04-07 | 2025-12-05 |
| Hepatitis C Treatment in Idaho County Jails sofosbuvir/velpatasvir - Hepatitis C | Not applicable | Unknown | Eastern Idaho Public Health | 100 | 2024-08-01 | 2024-08-01 |
| Therapy for Hepatitis C Virus (HCV) in Primary Treatment Failure in Pakistan Epclusa (nucleotide HCV NS5B polymerase inhibitors). - Hepatitis C | Not applicable | Enrolling by invitation | Queen Mary University of London | 318 | 2023-06-01 | 2025-11-21 |
| Elimination of Hepatitis C Virus Among Users of Substances Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa] - Hepatitis C in Substance Users | Unknown | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | 1000 | 2022-11-15 | 2022-09-29 | |
| Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis Sofosbuvir/Velpatasvir + Ribavirin, Sofosbuvir/Velpatasvir/Voxilaprevir - Hepatitis C, Cirrhosis | Phase 4 | Unknown | Peking University People's Hospital | 100 | 2022-09-01 | 2022-07-21 |
| Preparing for the Final Phase of Hepatitis C Elimination. Cairns Final 30% Xpert HCV Viral load finger stick point of care test (Cepheid), Epclusa 400Mg-100Mg Tablet, Standard of care - Hepatitis C | Phase 4 | Completed | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | 606 | 2022-07-25 | 2023-11-13 |
| Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet - Hepatitis C, Chronic, Pregnancy; Infection | Phase 4 | Active not recruiting | Catherine Anne Chappell | 100 | 2022-04-04 | 2026-10-19 |
| The Efficacy and Safety of 12-week SOF/VEL Regimen Combined With Prophylactic Use of TAF for Treatment-naïve Genotype 1-6 HCV/HBV Co-infection Adult Patients With or Without Compensated Cirrhosis in China Tenofovir Alafenamide 25 MG, Sofosbuvir / Velpatasvir - Chronic Hepatitis C, Chronic Hepatitis B | Phase 4 | Unknown | Peking University First Hospital | 120 | 2021-08-01 | 2021-08-09 |
| A Trial of Transplanting Hepatitis C Kidneys Into Hepatitis C-Negative Kidney Recipients Epclusa - End Stage Renal Disease | Phase 2 | Completed | University of Pennsylvania | 201 | 2021-06-22 | 2026-03-12 |
| Treatment of Chronic Hepatitis C During Pregnancy With Sofosbuvir/Velpatasvir Sofosbuvir-Velpatasvir Drug Combination - Hepatitis C, Chronic | Phase 1 | Completed | Catherine Anne Chappell | 11 | 2020-10-22 | 2025-01-01 |
| HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial Velpatasvir/Sofosbuvir - Hepatocellular Carcinoma, Hepatitis C | Phase 4 | Completed | Alexandria University | 84 | 2020-10-05 | 2023-04-04 |
| The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus - Hepatitis C, Chronic | Phase 4 | Completed | University of California, San Francisco | 87 | 2020-07-01 | 2025-05-28 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir (SOF/VEL) Fixed-Dose Combination (FDC) and Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX ) FDC for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection SOF/VEL, SOF/VEL/VOX - Hepatitis C Virus Infection | Phase 3 | Completed | Gilead Sciences | 87 | 2020-01-03 | 2021-10-27 |
| Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis SOF/VEL - Hepatitis C Virus Infection | Phase 3 | Completed | Gilead Sciences | 37 | 2019-10-16 | 2022-04-20 |
| The Kentucky Viral Hepatitis Treatment Study Sofosbuvir/velpatasvir (Epclusa®) - Hepatitis C, Opioid-Related Disorders | Phase 4 | Completed | Jennifer Havens | 380 | 2019-09-23 | 2026-10-20 |
| A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams HCV RNA Point of Care, Sofosbuvir/velpatasvir, Glecaprevir/pibrentasvir - Hepatitis C | Not applicable | Completed | Kirby Institute | 101 | 2019-09-10 | 2023-01-17 |
Showing 20 of 85. Sign in to see all of them.
Hepatitis C (70) · Hepatitis C, Chronic (17) · Fibrosis (8) · Acquired Immunodeficiency Syndrome (4) · Opioid-Related Disorders (4) · Liver Diseases (3) · Bronchiolitis Obliterans Syndrome (2) · Carcinoma, Hepatocellular (2) · Cardiovascular Diseases (2) · Communicable Diseases (2) · Digestive System Diseases (2) · Hepatitis (2) · Hepatitis, Viral, Human (2) · Lung Diseases (2) · RNA Virus Infections (2)
Gilead Sciences (29) · Kirby Institute (3) · Atea Pharmaceuticals, Inc. (2) · Catherine Anne Chappell (2) · Duke University (2) · Massachusetts General Hospital (2) · National Taiwan University Hospital (2) · University of California, San Francisco (2) · University of Pennsylvania (2) · Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (1) · Ala'a Sharara (1) · Alexandria University (1) · Amit D Tevar, MD (1) · Baylor Research Institute (1) · Brigham and Women's Hospital (1)
United States (46) · Australia (13) · Canada (13) · New Zealand (13) · Puerto Rico (13) · Germany (11) · United Kingdom (11) · France (9) · Italy (7) · Spain (5) · Belgium (4) · China (4) · Japan (3) · Taiwan (3) · Thailand (3)
Catherine Chappell, MD, MSc (2) · Fernanda Silviera, MD (2) · John McNally, PhD (2) · Ahmed Kamal, MD, PhD (1) · Alexander Wong, MD (1) · Amit Tevar, MD (1) · Amy E Colson, MD MPH (1) · Anu M Osinusi, MD, MPH (1) · Anu Osinusi, MD (1) · Chen-Hua Liu, MD (1) · Claus Niemann, MD (1) · Elizabeth E Krans, MD, MSc (1) · Fredrick Kateera, MD, PhD (1) · Gaurav Gupta, MD (1)
PMID 27847279, PMID 26575258, PMID 36740893, PMID 28390869, PMID 29958855, PMID 26569658, PMID 26571066, PMID 27240903, PMID 27486033, PMID 27486034, PMID 28137593, PMID 28145032, PMID 28369210, PMID 28404069, PMID 28564569, PMID 29309592, PMID 29365309, PMID 29425396, PMID 30499360, PMID 30552056, PMID 30555048, PMID 30861150, PMID 30946553, PMID 31078622, PMID 31195062, PMID 31216086, PMID 31606437, PMID 31652392, PMID 31790766, PMID 32087176, PMID 32156618, PMID 33303567, PMID 33493697, PMID 33965006, PMID 34226208, PMID 34596223, PMID 35026142, PMID 35248212, PMID 35248213, PMID 35362522, PMID 35714311, PMID 35802063, PMID 36694361, PMID 36852107, PMID 36863287, PMID 37862013, PMID 38046041, PMID 38344130, PMID 38436921, PMID 38610138
2014 (5), 2016 (5), 2015 (4), 2018 (1), R01DA047952 (1), R21HD101996 (1), R34DA061732 (1), U01AI195193 (1), U01DK126654 (1), UM1AI068636 (1)